65.00

1.10% -0.72

Mirum Pharmaceuticals Inc (MIRM)

Overview News Price History Option Chain Financials Why MIRM Down? Discussions Forecast

Mirum Pharmaceuticals Inc stock is traded at $65.00, with a volume of 461.13K. It is down -1.10% in the last 24 hours and down -8.17% over the past month. Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Previous Close:

$65.72

Open:

$66.14

24h Volume:

461.13K

Relative Volume:

0.71

Market Cap:

$3.36B

Revenue:

$379.25M

Net Income/Loss:

$-77.34M

P/E Ratio:

-40.32

EPS:

-1.6122

Net Cash Flow:

$-27.87M

1W Performance:

-5.08%

1M Performance:

-8.17%

6M Performance:

+32.60%

1Y Performance:

+53.74%

1-Day Range:

$64.23

$66.48

1-Week Range:

$63.48

$69.88

52-Week Range:

$36.88

$78.54

Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile

Name

Mirum Pharmaceuticals Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

650-667-4085

Address

989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY

Employee

355

Twitter

@mirumpharma

Next Earnings Date

2024-11-04

Latest SEC Filings

MIRM's Discussions on Twitter

Compare MIRM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MIRM Mirum Pharmaceuticals Inc	65.00	3.40B	379.25M	-77.34M	-27.87M	-1.6122
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-24-25	Initiated	TD Cowen	Buy
Aug-11-25	Resumed	Stifel	Buy
May-19-25	Resumed	H.C. Wainwright	Buy
Apr-17-24	Initiated	Stifel	Buy
Dec-18-23	Reiterated	H.C. Wainwright	Buy
Nov-20-23	Resumed	JP Morgan	Overweight
Nov-13-23	Initiated	Morgan Stanley	Overweight
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-17-23	Resumed	Evercore ISI	Outperform
Sep-20-23	Initiated	JMP Securities	Mkt Outperform
Sep-01-22	Initiated	Citigroup	Buy
Sep-20-21	Initiated	JP Morgan	Overweight
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
Jul-31-20	Initiated	Piper Sandler	Overweight
Jun-25-20	Initiated	Robert W. Baird	Outperform
Aug-12-19	Initiated	Citigroup	Buy
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Guggenheim	Buy
Aug-12-19	Initiated	ROTH Capital	Buy
Aug-12-19	Initiated	Raymond James	Outperform

View All

Mirum Pharmaceuticals Inc Stock (MIRM) Latest News

06:28 AM

The week in pharma: action, reaction and insight – week to December 12 - The Pharma Letter

06:28 AM

Dec 13, 2025

Eventide Asset Management LLC Has $134.22 Million Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat

Dec 13, 2025